文献速递胸部肿瘤

KRAS驱动肺癌中LKB1缺失相关STING抑制

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
PubMed 文献 · Cancer Discov · 2018-10-08

KRAS驱动肺癌常灭活TP53和/或STK11/LKB1,其中KRAS-LKB1(KL)突变肺癌侵袭性强、缺乏PD-L1且对免疫检查点阻断(ICB)反应差。研究发现LKB1缺失通过DNMT1和EZH2活性亢进沉默STING表达,逃避胞质双链DNA感应,从而促进免疫逃逸。

要点

  • KL突变肺癌STING表达显著沉默,对胞质dsDNA不敏感。
  • LKB1缺失经DNMT1/EZH2亢进沉默STING,与SAM升高相关。
  • 外源STING可激活IRF3/STAT1并损伤KL细胞适应性。

核心结论

  • LKB1缺失通过沉默STING表达逃避胞质dsDNA感应,促进KRAS驱动肺癌免疫逃逸。

研究设计与样本

  • 基于KRAS驱动肺癌中TP53和/或STK11/LKB1灭活亚型的机制研究。

主要发现

  • KL突变肺癌STING表达显著沉默且对胞质dsDNA不敏感。
  • 该效应至少部分由SAM升高相关DNMT1和EZH2活性亢进介导,并被DNMT1上调强化。
  • KL细胞中外源STING激活TBK1下游IRF3和STAT1信号,因线粒体功能障碍相关胞质线粒体dsDNA病理性积累而损伤细胞适应性。

临床怎么用

  • KL突变肺癌对ICB反应差,恢复STING表达是潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)-mutant lung cancers are particularly aggressive, lack PD-L1, and respond poorly to immune checkpoint blockade (ICB). The mechanistic basis for this impaired immunogenicity, despite the overall high mutational load of KRAS-mutant lung cancers, remains obscure. Here, we report that LKB1 loss results in marked silencing of stimulator of interferon genes (STING) expression and insensitivity to cytoplasmic double-strand DNA (dsDNA) sensing. This effect is mediated at least in part by hyperactivation of DNMT1 and EZH2 activity related to elevated S-adenylmethionine levels and reinforced by DNMT1 upregulation. Ectopic expression of STING in KL cells engages IRF3 and STAT1 signaling downstream of TBK1 and impairs cellular fitness, due to the pathologic accumulation of cytoplasmic mitochondrial dsDNA associated with mitochondrial dysfunction. Thus, silencing of STING avoids these negative consequences of LKB1 inactivation, while facilitating immune escape. SIGNIFICANCE: Oncogenic KRAS-mutant lung cancers remain treatment-refractory and are resistant to ICB in the setting of LKB1 loss. These results begin to uncover the key underlying mechanism and identify strategies to restore STING expression, with important therapeutic implications because mitochondrial dysfunction is an obligate component of this tumor subtype.See related commentary by Corte and Byers, p. 16.This article is highlighted in the In This Issue feature, p. 1.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Kitajima S, Ivanova E, Guo S, et al. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2018. PMID: 30297358. doi:10.1158/2159-8290.CD-18-0689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。